Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 703 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: lenalidomide Clear all
Terminated Phase 1 Interventional

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

NCT01742793
View directory record Official record
Conditions
Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions
lenalidomide (Revlimid) and romidepsin (Istodax)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 22, 2026, 4:55 PM EDT
Recruiting Phase 1Phase 2 Interventional

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03011814
View directory record Official record
Conditions
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Lenalidomide
Biological · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
4
States / cities
Duarte, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00602836
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, Cyclophosphamide, Lenalidomide, Pentostatin
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 1 Interventional Results available

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

NCT02954406
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
TAK-659, Bendamustine, Rituximab, Gemcitabine, Lenalidomide, Ibrutinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

NCT03290950
View directory record Official record
Conditions
Multiple Myeloma
Interventions
daratumumab, carfilzomib, lenalidomide, dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

NCT07605416
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
10
States / cities
New Haven, Connecticut • North Haven, Connecticut • Baton Rouge, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
tafasitamab, rituximab, lenalidomide, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
38
States / cities
Concord, California • Greenbrae, California • Pasadena, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Withdrawn Phase 2 Interventional

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

NCT03785184
View directory record Official record
Conditions
Multiple Myeloma
Interventions
venetoclax, lenalidomide, dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Duarte, California • Greenbrae, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

NCT00807599
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

NCT04352205
View directory record Official record
Conditions
Plasma Cell Myeloma, Renal Failure
Interventions
Bortezomib, Daratumumab, Dexamethasone, Lenalidomide, Thalidomide
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Rituximab, Lenalidomide
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

NCT00737529
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
31
States / cities
Little Rock, Arkansas • La Jolla, California • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Venetoclax, Umbralisib, Ublituximab, Lenalidomide
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

NCT01038388
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Vorinostat
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

NCT00495872
View directory record Official record
Conditions
Solid Tumors
Interventions
Dasatinib, Erlotinib, Lapatinib, Lenalidomide, Sorafenib, Sunitinib, Valproic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

NCT01133275
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS
Interventions
Prednisone, Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042
View directory record Official record
Conditions
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

NCT01583283
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215, lenalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 1 Interventional

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACE-011, Lenalidomide, Dexamethasone, Pomalidomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Lenalidomide Plus Chemotherapy for AML

NCT01681537
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Lenalidomide, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

NCT01946477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Daratumumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
33
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

NCT00466895
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Interventions
lenalidomide
Drug
Lead sponsor
Leslie Andritsos
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma

NCT01793051
View directory record Official record
Conditions
Myeloma
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00474188
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
CC-5013 (lenalidomide), dexamethasone
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 22, 2026, 4:55 PM EDT